Literature DB >> 33457411

miR-1929-3p Overexpression Alleviates Murine Cytomegalovirus-Induced Hypertensive Myocardial Remodeling by Suppressing Ednra/NLRP3 Inflammasome Activation.

YongJia Wang1, Zhen Huang1, Hua Zhong1, LaMei Wang2, DongMei Xi1, YunZhong Shi1, Wei Zhou1, YongMin Liu1, Na Tang1, Fang He1.   

Abstract

MicroRNAs (miRNAs) play crucial roles in the development of essential hypertension (EH). Previously, we found that the expression of miR-1929-3p was decreased in C57BL/6 mice with hypertension induced by murine cytomegalovirus (MCMV). In this study, we explored the role of miR-1929-3p in hypertension myocardial remodeling in MCMV-infected mice. First, we measured MCMV DNA and host IgG and IgM after infection and determined the expression of miR-1929-3p and its target gene endothelin A receptor (Ednra) mRNA in the myocardium of mice. Then, we performed invasive blood pressure (BP) monitoring. Heart-to-body weight ratio (HW/BW%), along with mRNA levels of B-type natriuretic peptide (BNP) and beta myosin heavy chain (β-MHC), revealed myocardial remodeling. Hematoxylin/eosin and Masson's trichrome staining indicated morphological changes in the myocardium. Cardiac function was assessed via echocardiography. Moreover, MCMV-infected mice were injected with recombinant adeno-associated virus- (rAAV-) miR-1929-3p overexpression vector. Immunohistochemistry and western blotting showed the expression of Ednra and the activation of NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome. And enzyme-linked immunosorbent assay (ELISA) revealed the concentrations of endothelin-1 (ET-1), interleukin-1β (IL-1β), and interleukin-18 (IL-18). In this study, we found that decreased expression of miR-1929-3p in MCMV-infected mice induced high BP and further development of myocardial remodeling cardiac function injury through increased expression of Ednra. Strikingly, overexpression of miR-1929-3p ameliorated these pathological changes of the heart. The positive effect was shown to be associated with inhibition of NLRP3 inflammasome activation and decreased expression of key proinflammatory cytokine IL-1β. Collectively, these results indicate that miR-1929-3p overexpression may effectively alleviate EH myocardial remodeling by suppressing Ednra/NLRP3 inflammasome activation in MCMV-infected mice.
Copyright © 2020 YongJia Wang et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33457411      PMCID: PMC7787724          DOI: 10.1155/2020/6653819

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  42 in total

1.  Variants of tumor necrosis factor-induced protein 3 gene are associated with left ventricular hypertrophy in hypertensive patients.

Authors:  Hao Xue; Shu-Xia Wang; Xiao-Jian Wang; Ying Xin; Hu Wang; Xiao-Dong Song; Kai Sun; Yi-Bo Wang; Ru-Tai Hui
Journal:  Chin Med J (Engl)       Date:  2011-05       Impact factor: 2.628

Review 2.  MicroRNAs in large herpesvirus DNA genomes: recent advances.

Authors:  Océane Sorel; Benjamin G Dewals
Journal:  Biomol Concepts       Date:  2016-08-01

3.  High-resolution human cytomegalovirus transcriptome.

Authors:  Derek Gatherer; Sepehr Seirafian; Charles Cunningham; Mary Holton; Derrick J Dargan; Katarina Baluchova; Ralph D Hector; Julie Galbraith; Pawel Herzyk; Gavin W G Wilkinson; Andrew J Davison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-22       Impact factor: 11.205

Review 4.  Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases.

Authors:  Dongling Liu; Xiang Zeng; Xiao Li; Jawahar L Mehta; Xianwei Wang
Journal:  Basic Res Cardiol       Date:  2017-12-09       Impact factor: 17.165

Review 5.  Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.

Authors:  Michael J Cannon; D Scott Schmid; Terri B Hyde
Journal:  Rev Med Virol       Date:  2010-07       Impact factor: 6.989

6.  Macrophage NLRP3 inflammasome activated by CVB3 capsid proteins contributes to the development of viral myocarditis.

Authors:  Jingyin Bao; Tianle Sun; Yan Yue; Sidong Xiong
Journal:  Mol Immunol       Date:  2019-07-20       Impact factor: 4.407

7.  Comparison of conventional, immunological and molecular techniques for the diagnosis of symptomatic congenital human cytomegalovirus infection in neonates and infants.

Authors:  A Choudhary; S K Pati; R K Patro; A K Deorari; L Dar
Journal:  Indian J Med Microbiol       Date:  2015-02       Impact factor: 0.985

8.  MiR-135b protects cardiomyocytes from infarction through restraining the NLRP3/caspase-1/IL-1β pathway.

Authors:  Anqi Li; Yahan Yu; Xueying Ding; Ying Qin; Yanan Jiang; Xinyao Wang; Guanqun Liu; Xi Chen; Er Yue; Xi Sun; Syeda M Zahra; Yan Yan; Long Ren; Shuo Wang; Lu Chai; Yunlong Bai; Baofeng Yang
Journal:  Int J Cardiol       Date:  2019-11-17       Impact factor: 4.164

9.  High anti-human cytomegalovirus antibody levels are associated with the progression of essential hypertension and target organ damage in Han Chinese population.

Authors:  Zhen Li; Yan Tang; Na Tang; Qian Feng; Hua Zhong; Yong-Min Liu; La-Mei Wang; Fang He
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

10.  Unexpected role of the human cytomegalovirus contribute to essential hypertension in the Kazakh Chinese population of Xinjiang.

Authors:  Qian Feng; Jing Hui; Na Tang; Yong-Min Liu; Hua Zhong; Zhen Li; La-Mei Wang; Yuan-Yuan Qu; Feng-Mei Deng; Fang He
Journal:  Biosci Rep       Date:  2018-06-27       Impact factor: 3.840

View more
  2 in total

Review 1.  How do pre-operative intra-articular injections impact periprosthetic joint infection risk following primary total hip arthroplasty? A systematic review and meta-analysis.

Authors:  Amanda Avila; Michael T Do; Alexander J Acuña; Linsen T Samuel; Atul F Kamath
Journal:  Arch Orthop Trauma Surg       Date:  2022-02-12       Impact factor: 3.067

Review 2.  The Role of Melatonin on NLRP3 Inflammasome Activation in Diseases.

Authors:  Burak Ibrahim Arioz; Emre Tarakcioglu; Melis Olcum; Sermin Genc
Journal:  Antioxidants (Basel)       Date:  2021-06-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.